Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that ...

AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday that it has completed dosing the final patient in its Phase 2b ...
Pharmabiz

EnteroBiotix begins patient dosing in phase 2b RISE study of EBX-102-02 in irritable bowel syndrome with constipation

EnteroBiotix begins patient dosing in phase 2b RISE study of EBX-102-02 in irritable bowel syndrome with constipation: Glasgow, Scotland Wednesday, July 8, 2026, 10:00 Hrs [IST] E ...

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reportedSOUTH SAN ...
Nasdaq

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
Pharmabiz

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression: New York Tuesday, July 7, 2026, 10:00 Hrs [IST] AtaiBeckley Inc.
Nasdaq

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) ...